Skip to main content

Table 1 Baseline characteristics

From: Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

  T2DM (n = 56) Non T2DM (n = 114) All(n = 170) p-value
Age,median (range) 66 (49–81) 63 (37–87) 64 (37–87) 0.094
Gender,n (%)
 Male 51 (91.1%) 97 (85.1%) 148 (87%)  
 Female 5 (8.9%) 17 (14.9%) 22 (13%) 0.337
Smoking history, n (%)
 Current 27 (48.2%) 57 (50%) 84 (49.4%)  
 Former 24 (42.8%) 51 (44.7%) 75 (44.1%)  
 Never 3 (5.4%) 4 (3.5%) 7 (4.1%)  
 Unknown 2 (3.6%) 2 (1.8%) 4 (2.4%) 0.837
ECOG PS, n (%)
 PS 0–1 53 (94.6%) 102 (90.3%) 155 (91.1%)  
 PS 2 3 (5.4%) 12 (9.7%) 15 (8.9%) 0.331
Histology n (%)
 Adenocarcinoma 9 (16%) 48 (42.1%) 57 (33.5%)  
 Squamous 29 (51.8%) 43 (37.7%) 72 (42.3%)  
 NOS 18 (32.2%) 23 (20.2%) 41 (24.2%) 0.003
Stage, n (%)
 IIIA 31 (55.3%) 54 (47.4%) 85 (50%)  
 IIIB 23 (41.1%) 58 (50.9%) 81 (47.6%) 0.321
Mean baseline glycemia (mmol/L) 9.22 ± 6.35 5.6 ± 1.2 6.75 ± 4.70 < 0.001
Comorbidities
 Any 34 (60.7%) 69 (60.5%) 103 (60.6%) 0.981
 Renal Insufficiency 5 (8.9%) 7 (6.1%) 12 (7.1%) 0.445
 COPD 21 (37.5%) 50 (44%) 71 (41.8%) 0.604
 Cardiovascular
 Hepatopathy
18 (32.1%)
2 (3.6%)
16 (14%)
0 (0%)
34 (20%)
2 (1.2%)
0.003
1.000
Platinum doublet, n (%)
 Cisplatin 27 (48.2%) 77 (67.5%) 104 (61.2%)  
 Carboplatin 29 (51.7%) 37 (32.5%) 66 (38.8%) 0.019
Total dose of RDT between 60-70Gys 54 (96.4%) 106 (93%) 160 (94%) 0.716
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, COPD chronic obstructive pulmonary disease, NOS not otherwise specified, RDT radiotherapy, T2DM type 2 diabetes mellitus